Intellia Therapeutics Inc (NTLA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Intellia Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 10.80 $ — 14% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
5/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 17.0%
- Exp. sales growth 3Y > 5% 101.1%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 101.1%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -61.5%
- ROCE > 15% -59.7%
- Expected return > 10% 55.7%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 9.1% failed
- More than 10% revenue growth is expected for the coming year 343.4% passed
- Share count grows by less than 3% a year 12.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -507.2% failed
- Gross margin at 40% or higher and without meaningful erosion 76.5% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 357 m net cash passed
- Operating cash flow covers the profits of the last three years 321 m failed
- Return on capital at 15% or higher, or up versus two years ago -59.7% failed
- Insiders hold at least 10% or are net buyers 3.9% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 140.2% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 29
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.13 | -3.63 – -2.76 | 59 | 17.7% | 16 |
| 12/31/2027 | -1.73 | -4.00 – 12.95 | 274 | 44.9% | 16 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.80 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.27 | – | 13 | – | -1,001.20 | -85 | -86 |
| 2025: Q1 | -1.10 | – | 17 | -42.50 | -687.60 | -149 | -150 |
| 2025: Q2 | -0.98 | – | 14 | 104.80 | -710.80 | -100 | -100 |
| 2025: Q3 | -0.92 | – | 14 | 51.30 | -735.20 | -77 | -77 |
| 2025: Q4 | -0.88 | – | 23 | 78.80 | -416.20 | -69 | -69 |
| 2026: Q1 | -0.81 | – | 15 | -9.50 | -639.50 | -117 | -117 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 16 | -32 | -32 | -0.91 | 36 | 210 | 299 |
| 2017 | 26 | -70 | -68 | -1.88 | -65 | 301 | 376 |
| 2018 | 30 | -91 | -85 | -1.98 | -61 | 278 | 347 |
| 2019 | 43 | -106 | -100 | -2.11 | -103 | 270 | 334 |
| 2020 | 58 | -137 | -126 | -2.24 | -50 | 527 | 676 |
| 2021 | 33 | -268 | -260 | -3.66 | -225 | 1,040 | 1,294 |
| 2022 | 52 | -458 | -474 | -6.16 | -333 | 1,236 | 1,520 |
| 2023 | 36 | -515 | -481 | -5.42 | -394 | 1,050 | 1,301 |
| 2024 | 58 | -534 | -519 | -5.25 | -349 | 872 | 1,191 |
| 2025 | 68 | -441 | -413 | -3.81 | -349 | 671 | 842 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Intellia Therapeutics, Inc. ist ein Unternehmen für Genom-Editierung in der klinischen Phase, das sich auf die Entwicklung potenziell heilender Therapeutika mit CRISPR/Cas9-basierten Technologien konzentriert.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 377 |
| Headquarters | Cambridge, MA |
| Address | 40 Erie Street, 02139 Cambridge, United States |
| Phone | 857 285 6200 |
| Website | intelliatx.com |
| IPO Date | 6. May 2016 |
| ISIN | US45826J1051 |
Management
| Name | Title | Birth Year |
|---|---|---|
| John M. Leonard M.D. | President, CEO & Director | 1957 |
| Edward J. Dulac III | Executive VP, CFO & Treasurer | 1976 |
| Birgit Schultes Ph.D. | Executive VP & Chief Scientific Officer | 1963 |
| James E. Basta Esq., J.D. | Executive VP, General Counsel & Corporate Secretary | 1966 |
| David Lebwohl M.D. | Executive VP & Chief Medical Officer | 1955 |
| Rachel E. Haurwitz Ph.D. | Co-Founder | 1986 |
| Jennifer A. Doudna Ph.D. | Founder & Member of Scientific Advisor Board | 1964 |
| Derrick J. Rossi Ph.D. | Founder & Member of Scientific Advisor Board | – |
| Rodolphe Barrangou M.B.A., Ph.D. | Founder & Member of Scientific Advisor Board | – |
| Prof. Luciano Marraffini Ph.D. | Founder & Member of Scientific Advisor Board | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.